Aradigm News

Total revenue was $0.3 million for the first quarter of 2012, compared with $0.2 million in revenue for the first quarter of 2011.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia HAYWARD, Calif.-- --Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2011.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Aradigm Corporation Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquina in Patients with Non-Cystic Fibrosis Bronchiectasis HAYWARD, Calif.-- --Aradigm ... (more)

Aradigm Corporation today announced that the Company's Investigational New Drug Application to conduct a pivotal Phase 3 clinical trial of Pulmaquin in non- cystic fibrosis bronchiectasis has been cleared by the U.S. Food and Drug Administration .

Aradigm Corporation Release: US Patent Protection for Pulmaquina its Extended with Issuance of a Composition of Matter Patent HAYWARD, Calif.-- --Aradigm Corporation today announced that the United States Patent and Trademark Office has issued an important composition of matter patent covering formulations of liposomal and free ciprofloxacin, ... (more)